FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for effective weight-loss drugs.

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... The near-10% compound annual growth rate predicted by the analysts reflects the late-phase pipeline.

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

Novo Nordisk has also struggled to keep up with demand for its GLP-1 rivals to Mounjaro and Zepbound, which are marketed as Ozempic and Wegovy, respectively. In late October, the FDA listed the ...

The agency allowed the pharmacies and outsourcing facilities to compound, distribute ... to reverse FDA’s determination that Mounjaro and Zepbound are not in shortage, so Plaintiffs can claim ...